Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: A meta-analysis of randomized trials performed with stents and thienopyridines

Clinical Cardiology

Volumn 35, Issue 2, 2012, Pages 93-100

  Winchester, David E ^a   Brearley, William D ^a   Wen, Xuerong ^b   Park, Ki E ^a   Bavry, Anthony A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; PLACEBO; THIENOPYRIDINE DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; COCHRANE LIBRARY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR BLEEDING; MEDLINE; META ANALYSIS; MINOR BLEEDING; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HEPARIN; HUMANS; MORTALITY; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 84857063772     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20974     Document Type: Article

References (43)

1. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006; 48: 1319-1325. (Pubitemid 44436821)
2. Keeley EC, Boura JA, Grines CL., Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13-20. (Pubitemid 36050955)
3. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Reopro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators. Circulation. 1998; 98: 734-741. (Pubitemid 28391837)
4. EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein iib/iiia receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994; 330: 956-961.
5. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005; 293: 1759-1765.
6. Le May MR, Wells GA, Glover CA, et al. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Interv. 2009; 2: 330-338.
7. De Luca G, Navarese E, Marino P., Risk profile and benefits from GP IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009; 30: 2705-2713.
8. Winchester DE, Bavry AA., Limitations of the medline database in constructing meta-analyses. Ann Intern Med. 2010; 153: 347-348.
9. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial - Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988; 11: 1-11. (Pubitemid 18029027)
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700.
11. Juni P, Altman DG, Egger M., Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001; 323: 42-46. (Pubitemid 32682008)
12. Begg CB, Mazumdar M., Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101.
13. Egger M, Davey Smith G, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. (Pubitemid 27387172)
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560. (Pubitemid 37088507)
15. ten Berg JM, vant̀ Hof AW, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010; 55: 2446-2455.
16. Vant̀ Hof AW, Ten Berg J, Heestermans T, et al. Ongoing Tirofiban In Myocardial Infarction Evaluation 2 Study G. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (ON-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008; 372: 537-546.
17. Mehilli J, Kastrati A, Schulz S, et al. Bavarian Reperfusion Alternatives Evaluation-3 Study I. Abciximab in patients with acute st-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009; 119: 1933-1940.
18. Ivandic BT, Kurz K, Keck F, et al. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes. Thromb Haemost. 2008; 100: 648-654.
19. Fu XH, Hao QQ, Jia XW, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J (Engl). 2008; 121: 522-527.
20. Shen J, Zhang Q, Zhang RY., Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35: 1005-1009.
21. Kastrati A, Mehilli J, Neumann FJ, et al. Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA. 2006; 295: 1531-1538.
22. Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J. 2005; 150: 1015.
23. Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004; 44: 1187-1193. (Pubitemid 39208872)
24. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial. J Am Coll Cardiol. 2004; 44: 14-19. (Pubitemid 38968448)
25. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003; 42: 1879-1885. (Pubitemid 37485558)
26. Petronio AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003; 24: 67-76. (Pubitemid 36109548)
27. Wong P, Harding S, Inglessis I, et al. The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study. J Thromb Thrombolysis. 2003; 16: 163-166. (Pubitemid 39137441)
28. Stone GW, Grines CL, Cox DA, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346: 957-966. (Pubitemid 34983245)
29. Montalescot G, Barragan P, Wittenberg O, et al. ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001; 344: 1895-1903.
30. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000; 35: 915-921. (Pubitemid 30189922)
31. Heestermans AA, Van Werkum JW, et al. Acute and subacute stent thrombosis after primary PCI for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. J Thromb Haemost. 2010; 8: 2385-2393.
32. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009; 53: 1399-1409.
33. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the Multistrategy Randomized Trial. JAMA. 2008; 299: 1788-1799. (Pubitemid 351549970)
34. Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute st-segment elevation myocardial infarction: results of the EVA-AMI trial. J Am Coll Cardiol. 2010; 56: 463-469.
35. Gurm HS, Tamhane U, Meier P, et al. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Interv. 2009; 2: 230-236.
36. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with st-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol. 2009; 53: 1668-1673.
37. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001; 103: 2572-2578. (Pubitemid 32521967)
38. Lindsey JB, Marso SP, Pencina M, et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv. 2009; 2: 1074-1082.
39. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007; 49: 1362-1368. (Pubitemid 46476844)
40. Fung AY, Saw J, Starovoytov A, et al. Abbreviated infusion of eptifibatide after successful coronary intervention the BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol. 2009; 53: 837-845.
41. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008; 118: 49-57.
42. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355: 2203-2216. (Pubitemid 44791162)
43. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358: 2218-2230. (Pubitemid 351724451)